omitir hasta el contenido
Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance Ver este material de antemano
CerrarVer este material de antemano
Chequeando…

Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance

Autor: Benjamin Bonavida
Editorial: New York, NY : Springer, 2013.
Serie: Resistance to targeted anti-cancer therapeutics, v.2
Edición/Formato:   Libro-e : Documento : Inglés (eng)Ver todas las ediciones y todos los formatos
Base de datos:WorldCat
Resumen:
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops  Leer más
Calificación:

(todavía no calificado) 0 con reseñas - Ser el primero.

Temas
Más materiales como éste

 

Encontrar un ejemplar en línea

Enlaces a este material

Encontrar un ejemplar en la biblioteca

&AllPage.SpinnerRetrieving; Encontrando bibliotecas que tienen este material…

Detalles

Género/Forma: Electronic books
Tipo de material: Documento, Recurso en Internet
Tipo de documento: Recurso en Internet, Archivo de computadora
Todos autores / colaboradores: Benjamin Bonavida
ISBN: 9781461476542 1461476542
Número OCLC: 857224719
Notas: Includes index.
Descripción: 1 online resource (xiii, 202 pages) : illustrations.
Contenido: Resistance to Anticancer Antibodies: From Mechanisms to Solutions / Lina Reslan, Charles Dumontet --
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence / Yangyang Wang, Francesco Sabbatino, Ling Yu --
Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors / Emily L. Williams, Sean H. Lim --
Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance / Francisco J. Hernandez-Ilizaliturri --
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype / Benjamin Bonavida --
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer / Zacharenia Saridaki, John Souglakos --
Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors / Peter Hersey, Stuart Gallagher --
Strategies to Overcome TRAIL Resistance in Cancer / Simone Fulda --
Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics / Vaughn Smider --
Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance? / Penelope M. Drake, David Rabuka.
Título de la serie: Resistance to targeted anti-cancer therapeutics, v.2
Responsabilidad: Benjamin Bonavida, editor.
Más información:

Resumen:

Resistance to Immunotherapeutic Antibodies in Cancer  Leer más

Reseñas

Reseñas contribuidas por usuarios
Recuperando reseñas de GoodReads…
Recuperando reseñas de DOGObooks…

Etiquetas

Ser el primero.
Confirmar este pedido

Ya ha pedido este material. Escoja OK si desea procesar el pedido de todos modos.

Datos enlazados


<http://www.worldcat.org/oclc/857224719>
library:oclcnum"857224719"
library:placeOfPublication
owl:sameAs<info:oclcnum/857224719>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:datePublished"2013"
schema:description"The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1754943023>
schema:genre"Electronic books."
schema:inLanguage"en"
schema:name"Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance"
schema:url<http://lib.myilibrary.com?id=517004>
schema:url
schema:url
schema:url<http://site.ebrary.com/id/10743790>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=622877>
schema:workExample
schema:workExample

Content-negotiable representations

Cerrar ventana

Inicie una sesión con WorldCat 

¿No tienes una cuenta? Puede fácilmente crear una cuenta gratuita.